Advisors Asset Management Inc. Has $18.78 Million Position in Eli Lilly and Company $LLY

Advisors Asset Management Inc. trimmed its stake in shares of Eli Lilly and Company (NYSE:LLY) by 7.7% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 24,096 shares of the company’s stock after selling 2,016 shares during the quarter. Advisors Asset Management Inc.’s holdings in Eli Lilly and Company were worth $18,784,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Wealth Preservation Advisors LLC bought a new position in Eli Lilly and Company in the 1st quarter valued at approximately $27,000. Financial Gravity Companies Inc. bought a new position in shares of Eli Lilly and Company in the 2nd quarter valued at $31,000. Blume Capital Management Inc. boosted its holdings in shares of Eli Lilly and Company by 46.7% during the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock valued at $34,000 after acquiring an additional 14 shares in the last quarter. IMG Wealth Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at $35,000. Finally, TD Capital Management LLC increased its holdings in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 0.8%

Shares of Eli Lilly and Company stock opened at $1,067.68 on Tuesday. The company has a market capitalization of $1.01 trillion, a P/E ratio of 69.78, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. The stock has a fifty day simple moving average of $862.28 and a 200 day simple moving average of $790.04. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,075.72. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the firm earned $1.18 EPS. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be given a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on LLY. Berenberg Bank reissued a “hold” rating and set a $830.00 target price (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Leerink Partners raised shares of Eli Lilly and Company from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $886.00 to $1,104.00 in a research note on Monday, November 10th. Sanford C. Bernstein raised their target price on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the stock an “outperform” rating in a research report on Monday. Deutsche Bank Aktiengesellschaft reduced their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Finally, Truist Financial raised their price objective on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,047.50.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.